Literature DB >> 31570557

Association of TRAF1/C5 Locus Polymorphisms with Epilepsy and Clinical Traits in Mexican Patients with Neurocysticercosis.

Marcela Villegas1, Edda Sciutto2, Marcos Rosetti2,3, Agnes Fleury2,4, Gladis Fragoso5.   

Abstract

Neurocysticercosis is caused by the establishment of Taenia solium cysts in the central nervous system. Murine cysticercosis by Taenia crassiceps is a useful model of cysticercosis in which the complement component 5 (C5) has been linked to infection resistance/permissiveness. This work aimed to study the possible relevance for human neurocysticercosis of single nucleotide polymorphisms (SNPs) in the C5-TRAF1 region (rs17611 C/T, rs992670 G/A, rs25681 G/A, rs10818488 A/G, and rs3761847 G/A) in a Mexican population and associated with clinical and radiological traits related to neurocysticercosis severity (cell count in the cerebrospinal fluid [CSF cellularity], parasite location and parasite load in the brain, parasite degenerating stage, and epilepsy). The AG genotype of the rs3761847 SNP showed a tendency to associate with multiple brain parasites, while the CT and GG genotypes of the rs17611 and rs3761847 SNPs, respectively, showed a tendency to associate with low CSF cellularity. The rs3761847 SNP was associated with epilepsy under a dominant model, whereas rs10818488 was associated with CSF cellularity and parasite load under dominant and recessive models, respectively. For haplotypes, C5- and the TRAF1-associated SNPs were, respectively, in strong linkage disequilibrium with each other; thus, these haplotypes were studied independently. For C5 SNPs, carrying the CAA haplotype increases the risk of showing high CSF cellularity 3-fold and the risk of having extraparenchymal parasites 4-fold, two conditions that are related to severe disease. For TRAF1 SNPs, the GA and AG haplotypes were associated with CSF cellularity, and the AG haplotype was associated with epilepsy. Overall, these findings support the clear participation of C5 and TRAF1 in the risk of developing severe neurocysticercosis in the Mexican population.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  C5 complement; SNP; TRAF1; TRAF1/C5; association; genetic polymorphism; neurocysticercosis

Mesh:

Substances:

Year:  2019        PMID: 31570557      PMCID: PMC6867841          DOI: 10.1128/IAI.00347-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions.

Authors:  E Sciutto; G Fragoso; A Fleury; J P Laclette; J Sotelo; A Aluja; L Vargas; C Larralde
Journal:  Microbes Infect       Date:  2000-12       Impact factor: 2.700

Review 2.  The relationship between neurocysticercosis and epilepsy: an endless debate.

Authors:  Arturo Carpio; Matthew L Romo
Journal:  Arq Neuropsiquiatr       Date:  2014-05       Impact factor: 1.420

Review 3.  The Many Faces of Neurocysticercosis.

Authors:  Pooja Raibagkar; Aaron L Berkowitz
Journal:  J Neurol Sci       Date:  2018-04-12       Impact factor: 3.181

4.  Relationship between the clinical heterogeneity of neurocysticercosis and the immune-inflammatory profiles.

Authors:  Anahí Chavarría; Agnes Fleury; Esperanza García; Carlos Márquez; Gladis Fragoso; Edda Sciutto
Journal:  Clin Immunol       Date:  2005-09       Impact factor: 3.969

5.  Anti-GK1 antibodies damage Taenia crassiceps cysticerci through complement activation.

Authors:  Guadalupe Núñez; Nelly Villalobos; Cinthia P Herrera; José Navarrete-Perea; Adriana Méndez; José J Martinez-Maya; Raúl J Bobes; Gladis Fragoso; Edda Sciutto; Laura Aguilar; Irene P Del Arenal
Journal:  Parasitol Res       Date:  2018-06-06       Impact factor: 2.289

6.  Single-Nucleotide Polymorphism rs17611 of Complement Component 5 Shows Association with Ischemic Stroke in Northeast Chinese Population.

Authors:  Liang Guo; Liqiang Zheng; Xiaofan Guo; Ye Chang; Xinghu Zhou; Yingxian Sun
Journal:  Genet Test Mol Biomarkers       Date:  2016-10-21

7.  Toll-like receptor 4 polymorphism and its association with symptomatic neurocysticercosis.

Authors:  Avantika Verma; Kashi Nath Prasad; Rakesh Kumar Gupta; Aloukick Kumar Singh; Kishan Kumar Nyati; Arshi Rizwan; Chandra Mohan Pandey; Vimal Kumar Paliwal
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

8.  TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study.

Authors:  Robert M Plenge; Mark Seielstad; Leonid Padyukov; Annette T Lee; Elaine F Remmers; Bo Ding; Anthony Liew; Houman Khalili; Alamelu Chandrasekaran; Leela R L Davies; Wentian Li; Adrian K S Tan; Carine Bonnard; Rick T H Ong; Anbupalam Thalamuthu; Sven Pettersson; Chunyu Liu; Chao Tian; Wei V Chen; John P Carulli; Evan M Beckman; David Altshuler; Lars Alfredsson; Lindsey A Criswell; Christopher I Amos; Michael F Seldin; Daniel L Kastner; Lars Klareskog; Peter K Gregersen
Journal:  N Engl J Med       Date:  2007-09-05       Impact factor: 91.245

Review 9.  Complement in immune and inflammatory disorders: pathophysiological mechanisms.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 10.  Systematic review and meta-analysis estimating association of cysticercosis and neurocysticercosis with epilepsy.

Authors:  Gabrielle Debacq; Luz M Moyano; Héctor H Garcia; Farid Boumediene; Benoit Marin; Edgard B Ngoungou; Pierre-Marie Preux
Journal:  PLoS Negl Trop Dis       Date:  2017-03-07
View more
  2 in total

Review 1.  Host immune responses during Taenia solium Neurocysticercosis infection and treatment.

Authors:  Ulrich Fabien Prodjinotho; Jakobo Lema; Matthew Lacorcia; Veronika Schmidt; Nermina Vejzagic; Chummy Sikasunge; Bernard Ngowi; Andrea Sylvia Winkler; Clarissa Prazeres da Costa
Journal:  PLoS Negl Trop Dis       Date:  2020-04-16

Review 2.  Epileptogenesis in Common Parasitic Infections.

Authors:  Rajarshi Mazumder; John K Lee
Journal:  Curr Neurol Neurosci Rep       Date:  2022-03-25       Impact factor: 6.030

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.